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The in vivo and in vitro immunomodulatory effects of inter-
feron gamma (IFN-y) treatment on peripheral blood mono-
nuclear cells (PEMe) from patients with atopic dermatitis 
(AD) and elevated IgE levels were studied. As part of a dou-
ble-blind placebo-controlled clinical trial, 14 AD patients 
were treated with IFN-y (n = 7) or saline (n = 7) for 12 
weeks. To assess the in vivo effects of IFN-y treatment on 
interleukin (IL)-4 - dependent lymphocyte function, we as-
sessed the proliferation of AD PEMe in response to IL-4. 
Prior to IFN-y treatment, AD PEMe had proportionately 
decreased proliferative responses to IL-4 when compared to 
IL-2. After 12 weeks of in vivo treatment with IFN-y, there 
was an increase ofIL-4- but not IL-2-induced lymphocyte 
proliferation in seven of eight AD patients. 
To further study the immunologic basis of these observa-
A topic dermatitis (AD) is a chronic inflammatory skin disease that is frequently associated with markedly elevated serum immunoglobulin (Ig)E levels [1-3]. T lymphocytes are thought to play an important role in the pathogenesis of this disease [4]. It is now well 
established that interleukin (IL)-4 acts as an isotype switch factor for 
the induction of IgE synthesis [5 - 7] . In contrast, IFN-y inhibits 
IL-4-induced IgE production [8-12]. Studies of the murine im-
mune system have demonstrated that these cytokines are produced 
by different T-helper (TH) cell subpopulations [13]. It has also been 
found that IL-2 and IL-4 are intimately involved in the regulation of 
lymphocyte proliferation. As shown in several studies in human and 
mice, IL-2 and IL-4 are able to induce lymphocyte growth in an 
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Abbreviations: 
AD: atopic dermatitis 
ELISA: enzyme-linked immunosorbent assay 
IFN-y: interferon gamma 
Ig: immunoglobulin 
IL-2/IL-2R: interleukin 2/interleukin 2 receptor 
IL-4/IL-4R: interleukin 4/interleukin 4 receptor 
MCF: mean channel fluorescence 
PBMC: peripheral blood mononuclear cells 
PBS: phosphate-buffered saline 
PHA: phytohemagglutinin 
r: recombinant 
tions, we studied the expression of IL-4 receptor (IL-4 R) 
mRNA and the production of IL-4 by PEMe from AD pa-
tients. PEMe from AD patients expressed higher levels of 
IL-4R mRNA and produced significantly higher amounts of 
IL-4 than normal controls (p < 0.05). More importantly, the 
in vitro addition of IFN-y caused significant reduction in 
both IL-4R mRNA expression and IL-4 production of 
PEMe from AD and non-atopic controls. 
These data indicate that AD is characterized by an in vivo 
overstimulation of the IL-4-IL-4R pathway. The poor pro-
liferative responses of untreated AD PEMe to exogenous 
IL-4 may be due to increased levels of endogenous IL-4 pro-
duction with constant occupancy of the IL-4 R. Furthermore, 
in vivo and in vitro treatment with IFN-y down-regulates 
this pathway.] Invest Dermato199:403-408, 1992 
equal fashion [14-16] and, as demonstrated recently by our group 
and others, both IL act through independent pathways [17 -20]. 
Recently, there have been several reports that PBMC from pa-
tients with AD produce decreased levels ofIFN-y paralleled by an 
increase in IL-4 production [21- 23]. Furthermore, a high fre-
quency ofIL-4 producing but not IFN-y-producing CD4+ aller-
gen-specific T lymphocytes infiltrate into the inflammatory skin 
lesion of AD [24]. Such studies have provided the rationale for 
clinical trials of recombinant (r) IFN-y in the treatment of AD [25]. 
In a recent multi-center double-blind placebo-controlled trial, AD 
patients treated with rIFN-y had a significantly greater reduction in 
cli.nical.sever~ty than patients treated with placebo [26]. As part of 
thiS clmcal tnal, we assessed the in vivo and in vitro effects ofIFN-y 
treatment on the modulation ofIL-4- dependent lymphocyte func-
tions. Our current study demonstrates that AD is characterized by 
an in vivo upregulation of the IL-4 - IL-4 R pathway, which, in turn, 
is under the negative regulatory control of IFN-y. 
MATERIALS AND METHODS 
Study Population Fourteen patients with severe AD, who were 
enrolled as part of a double-blind placebo-controlled study assessing 
the efficacy of rIFN-y in AD, were studied [26] . All patients or 
guardians gave written informed consent prior to participation in 
the study. Patients were between the ages of7 and 53 years and had 
severe AD diagnosed according to the criteria of Hanifin et al [27]. 
Ten non-atopic healthy age-matched volunteers were studied as 
controls. 
In Vivo rIFN-y Treatment AD patients enrolled in the double-
blind placebo-controlled clinical trial were assigned to rIFN-y or 
placebo treatment by a randomized sequence generated by the Gen-
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entech, Inc., Biostatistics group [26]. rIFN-ywas received in asingle 
daily subcutaneous injection of 50 J1,g/m2 for 12 weeks. rIFN-y was 
supplied as a sterile solution ready for parenteral administration in 
0.1 mg/vial at a concentration of 0.2 mg/m!. Placebo was received 
by the same regimen and was supplied in an identical configuration 
and contained an equal volume of IFN-y diluent. Patients were 
permitted to use low- to medium-potency topical corticosteroids 
during the study. No patient was on systemic corticosteroids for at 
least 1 month prior to the study entry. All patients completed the 
study. Decoding at the end of the study revealed that seven AD 
patients had received rIFN-y and seven had received placebo. The 
mean age and the severity of the disease were comparable in both 
groups. All immunologic assays were performed in a blinded fash-
ion without knowledge about the treatment of the individual pa-
tients. 
Blood Sampling and Cell Preparations Heparinized blood 
was drawn at the beginning of the study and after receiving the last 
injection at the end of the 12-week tria!' Peripheral blood mononu-
clear cells (PBMe) were prepared by Ficoll-Hypaque gradient cen-
trifugation for 15 min at room temperature. The interphase was 
collected and washed three times in PBS for 5 minutes at 1500 rpm. 
Cells were counted and resuspended in RPM I 1640 tissue culture 
medium (Gibco, Grand Island, NY), supplemented with penicillin 
(100 U/ml), streptomycin (100 J1,g/ml), 2-mercaptoethanol 
(5 mM), L-glutamine (2 mM), and 10% heatooinactivated fetal calf 
serum. 
Lymphocyte Proliferation Assay The proliferative responses 
to IL-2 and IL-4 were assayed by incubating 0.2 X 106 PBMC in 
complete tissue culture medium in 96-well flat-bottom culture 
plates (Falcon, Lincoln Park, NY) for 72 h. Cells were pre-activated 
by addition of PHA in a concentration of 500 ng/ml, which was 
found to be a submitogenic dose [17] . IL-2 (kindly provided by 
Cetus, Emeryville, CA) was added in a concentration of 10 U/ml 
and IL-4 (kindly provided by Dr. Paul Trotta, Schering-Plough 
Research Institute, Bloomfield, NJ) was added at 200 U /m!. Both 
concentrations were found to induce maximal proliferation in nor-
mal donors. For at least 4-6 h (3H]thymidine (Amersham Corp., 
Arlington Heights, IL) was added (1 J1,Ci/well). Cells were har-
vested on a multi-channel Cambridge PhD cell harvester. (3H]TdR 
incorporation was measured in a beta scintillation counter. 
Analysis ofIL-4R mRNA by Northern Blotting Total cellu-
lar RNA was isolated by lysing cells in 300 mM NaAc, pH 5.5, 
10 mM EGTA, pH 8, 0.2% SDS, and 10 mg Na heparin Grade I 
(Sigma) as an RNAse inhibitor. Cell lysates were extracted once 
with phenol-chloroform at 65 °C followed by a second extraction at 
room temperature. Nucleic acids were ethanol precipitated and 
high-molecular-weight material was removed by centrifugation at 
1000 rpm for 1 min at room temperature. For Northern blotting, 
RNA (7.5 J1,g/lane) was separated by electrophoresis in 1 % agarose 
gels containing formaldehyde and blotted onto nylon membranes 
(Micron Separations, Inc., Westboro, MA). Membranes were pre-
hybridized for at least 5 h at 42 °C in 50% formamide, 5 X SSC, 
0.05 M NaPhosphate, 0.5% SDS, and 50 J1,g/mi salmon sperm 
DNA. Hybridization was performed overnight under the same 
conditions with a human IL-4R probe, as described [28,29], using 
the RNA transcription test (Stratagene, La Jolla, CA). The IL-4R 
probe was kindly provided by Dr. M. Patricia Beckmann, Immunex 
Corp., Seattle, W A. The GAPDH probe was provided by Dr. Ni-
shida, Kobe, Japan, and equivalent amounts of RNA/gel were as-
sessed by monitoring dehydrogenase GAPDH mRNA levels. 
Determination of IL-4 Production in Culture Supernatants 
IL-4 could not be reliably measured by commercially available en-
zyme-linked immunosorbent assay (ELISA) kits. We therefore as-
sessed IL-4 content by the capacity of supernatants to induce CD23 
on the CD23-negative Ramos B-celiline based on a biologic assay 
described by Custer and Lotze [30]. Ramos cells were subcultured 
with RPMI 1640 in complete culture medium. For experiments, 
only viable cells obtained from Ficoll-hypaque gradient centrifuga-
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Figure 1. Ratios of IL-2:IL-4 dependent lymphocyte proliferation in 14 
AD patients and six age-matched controls. PBMe (2 X 105) per well were 
preactivated with a submitogenic concentration of PHA (500 ng/ml) and 
further stimulated with either IL-2 (10 U/ml) or IL-4 (200 U/m!) for 3 d. 
The ratio of(3H] thymidine incorporation ofIL-2- and IL-4-treated cul-
tures was determined for each individual. The values between the groups are 
significantly (p < 0.05) different. 
tion were used. Cells were cultured in 96-well tissue culture plates 
(Falcon) in a concentration as 1 X 105 cells per well and stimulated 
with 5 J1,g/ml of anti-IgM (Tago, Burlingame, CA) . Either human 
rIL-4 in a concentration range between 1 and 100 U /ml or dilutions 
of tissue culture supernatants were added for 48 h. Cells were 
washed twice and reincubated with human immunoglobulins at 
10 mg/ml in order to prevent non-specific binding by Fc receptor. 
Subsequently, the cells were incubated with monoclonal anti-
CD23 antibody for 30 min in staining buffer [phosphate-buffered 
saline (PBS) supplemented with 2% heat-inactivated fetal calf 
serum and 0.1 % sodium azide] . After washing three times, CD23 
expression was determined for each sample and standard. A standard 
curve was then established for each assay by plotting of CD23 meau 
channel fluorescence (MCF) value against corresponding IL-4 con-
centrations of standard samples on a linear scale. Using this standard 
curve, MCF values of samples analyzed was transformed into IL-4 
concentrations. The specificity of this assay was demonstrated by 
the loss of CD23 induction on Ramos cells when samples were 
preincubated with anti-IL-4 antibodies. IFN-y did not interfere 
with the IL-4 assay because MoAb GIR208 (gift from Dr. R. 
Schreiber, St. Louis), which blocks the binding of IFN-y to its 
receptor, had no effect on the induction of CD23 by culture super- . 
natants . The sensitivity range of this assay ranged from 0.5 U /ml up 
to 100 U /ml of72-4; 16 supernatants contained higher amounts of 
lL-4. Further dilutions of the supernatants were analyzed. 
The following experiments were carried out to demonstrate the 
specificity of the assay: samples tested in the presence of polyclonal 
anti-1L4 (Genzyme, MA) lost their CD23-inducing activity. Be-
cause IFN-y is able to downregulate CD23 expression, all samples 
were pre incubated with anti-IFN-y antibody (Genentech, CA) to 
neutralize any IFN-y activity in the sample. Furthermore, addition 
of purified IgE (up to 50 ng/ml) to Ramos cells whose CD23 ex-
pression was induced by IL-4 did not affect the MCF values for 
CD23. 
Statistical Analysis Data were analyzed by two-tailed Student t 
test for unpaired samples and by the chi-squared test (Fig 1). 
RESULTS 
Impaired Proliferative Response tolL-4 in AD The prolifera-
tive responses to exogenous lL-2 and lL-4 was examined on PBMC 
from 14 atopic patients and six age-matched normal controls. The 
induction oflymphocyte responsiveness to interleukins requires cell 
preactivation. This was achieved by stimulation with a submito-
genic concentration of phytohemagglutinin (PHA) 500 ng/ml). As 
shown previously [17], in this way preactivated lymphocytes prolif-
erate in an equal fashion to optimal concentrations of IL-2 (10 U / 
ml) and IL-4 (200 U /ml). This results in an IL-2/1L-4 ratio of about 
1. Table I shows the proliferative response of one representative 
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Table I. Proliferative Responses of PBMC from One Normal 
Donor and Atopic Dermatitis Patient" 
Control 
PHA (500 mg/ml) 
PHA + IL-2 (10 U/ml) 
PHA + IL-4 (200 U/ml) 
Normal 
1065 ± 600 
5257 ± 1800 
52,010 ± 3980 
54,030 ± 3860 
Atopic Dermatis 
1470 ± 405 
4446 ± 1360 
67,486 ± 5840 
10,311 ± 690 
• Cells were cultured with medicated conditions as described in Materials and Methods 
for 72 h [' H] thymidine was added forthe last 6 h. The data are expressed as mean ± SO 
from triplicate cultures. 
normal and atopic donor to the stimulation of PHA-preactivated 
PBMC with IL-2 and IL-4. The incubation with the submitogenic 
concentration of PHA resulted in [3H]TdR incorporation of less 
than 5% of the maximal counts observed in the individual donors. 
In non-atopic subjects, the responses to IL-2 and IL-4 did not 
differ signili.cantly from each other. Atopic subjects always showed 
a response to the addition ofIL-2 comparable to the one measured in 
the control group. But, in contrast to non-atopic volunteers, 9 of the 
14 AD patients exhibit an IL-2/IL-4 ratio that was greater than 1 
(p < 0.05 compared to normal). IL-2/IL-4 ratios greater than 1 
were always the result of a decreased proliferative response to IL-4 
and a normal proliferative response to IL-2 (Fig 1). The remaining 
patients were characterized by a similar response to both interleu-
kins compared with the non-atopic donors, as indicated by a ratio of 
about 1. 
In Vivo rIFN -y Treatment Normalizes IL-4 - Dependent Pro-
literation of AD PBMC As part of a multi-center double-blind 
placebo-controlled trial, we reported that treatment with rIFN-y 
results in signili.cantly greater clinical improvement of AD signs and 
symptoms than placebo treatment [26]. PBMC from 14 patients 
who were part of this clinical trial were examined for their in vitro 
proliferative response to both IL-2 and IL-4 before the trial was 
started, and after 12 weeks oflFN-y or placebo treatment. Figure 2 
displays the IL-2/IL-4 ratios for each individual patient in the IFN-
y and placebo groups before and after treatment. Treatment with 
IFN-y signili.cantly reduced the IL-2/IL-4 ratio of AD patients 
(p = 0.02) . In contrast, no signili.cant changes were observed in the 
placebo-treated group (p = 0.8). The decrease ofIL-2/IL-4 ratio in 
the treated group was due to an increase of IL-4 - dependent lym-
phocyte proliferation, which increased between 200% and 500% 
(Fig 3). In contrast, the IL-2- induced response showed no signili.-
cant changes. These data indicate that in vivo IFN-y treatment 
increases the responsiveness of atopic PBMC to IL-4. 
IL-4 Production and IL-4 Receptor (IL-4R) are Enhanced in 
AD In order to examine whether the decreased in vitro prolifera-
tive response to IL-4 may be related to an altered regulation ofIL-4 
production or IL-4R expression in AD, the spontaneous and PHA-
induced release of IL-4 from PBMC was examined. For this pur-
pose, PBMC from AD patients and controls were incubated with or 
without PHA (10 ,ug/ ml). The kinetics of lL-4 release from PHA-
activated PBMC revealed that IL-4 production increased during the 
first 24 h, followed by a plateau during the second 24-h period (data 
not shown). Based on these kinetic experiments, the production of 
IL-4 was measured in 24-h culture supernatants. 
In unstimulated cultures from normal control donors, only two of 
nine donors had any detectable IL-4 production. In contrast, in six 
of nine AD patients spontaneous IL-4 production of up to 22 U /ml 
was detected (data not shown). Table II shows the results on IL-4 
production in PHA-stimulated cultures from two representative 
normal control donors and two patients with AD. Although PHA 
induced IL-4 production in all cases, signili.cantly higher amounts 
were detected in supernatants from patients with AD (p < 0.05) . 
These data indicate that AD is associated with increased spontane-
ous and PHA-stimulated IL-4 production. 
As it has been demonstrated that IL-4 is an important stimulator 
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Figure 2. Effects of IFN-y or placebo treatment on IL2/IL4 proliferative 
response in AD patients. The data were expressed as the ratio for each 
individual before and after completion of the clinical trial. Patients were 
assigned to IFN-y or placebo treatment as described in Materials and Methods. 
The individual proliferative responses to IL-2 and IL-4 were determined as 
described in Fig 1. 
for the up-regulation of its own receptor [32] , the expression of 
IL-4R was studied on the mRNA level by Northern blot analysis. 
The analysis ofIL-4R mRNA indicated that freshly isolated PBMC 
from AD patients expressed higher amounts of1L-4R mRNA than 
the controls (Fig 4A). Stimulation with PHA for 48 h enhanced 
IL-4R mRNA expression in both atopic and control subjects (Fig 
4B). 
In Vitro Treatment ofPBMC with IFN-y Reduces IL-4 Pro-
duction and IL-4R Expression It has been shown that IFN-y 
antagonizes a number of IL-4-dependent lymphocyte functions 
including the induction ofIgE synthesis [18 - 22]. The actual mecha-
nism by which IFN-y acts, however, is unknown. To examine 
wheth~r .the production ofIL-4 and the up-regulation ofIL-4R may 
be sensitive to rIFN-y, PHA-stimulated PBMC from AD patients 
and normal subjects were incubated in the presence and absence of 
rIFN-y. T able II shows the effect of IFN-y on PHA-induced IL-4 
production in PMBC from atopic and normal subjects. In all cases, 
IFN-y inhibited PHA-induced IL-4 production. This effect was 
observed in all of the nine studied AD patients as well as in four of 
four PBMC cultures of controls. In both groups, the IL-4 down-re-
gulation by IFN-y was signli.cant (p < 0.05). To some degree, IFN-
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Figure 3. Treatment with rIFN-y increases the proliferative response to 
IL-4 but not to IL-2. For the seven IFN-y- treated patients, the differences in 
the proliferation patterns to IL-4 and IL-2, before and after treatment, are 
expressed as percent changes. The response at the beginning of the trial was 
calculated as 100%. IL-4 - and IL-2 - induced lymphocyte proliferation was 
performed as described in Fig 1. The changes in IL-4 - induced proliferation 
are significantly higher (p < 0.01) than for IL-2. 
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Table II. IFN-y Inhibits Spontaneous and 
PHA-Induced IL-4 production" 
IL-4 (U/ml) 
-IFN-y +IFN-y 
126 ± 18 17 ± 6 
175 ± 36 25 ± 12 
578 ± 61 184 ± 21 
638 ± 112 102 ± 31 
• PBMC from 2 atopies (AD) and 2 normal controls were cultured with medium and 
PHA (10 Jig/ml) in the presence and absence oflFN-y (200 U/ml) for 24 h. Culture 
supernatants were harvested and analyzed for IL-4 production as described in Materials 
alld Metloods. Shown are the mean ± SD for triplicates of each condition. 
y also reduced IL-4 production by unstimulated PBMC from AD 
patients, but no significant differences were found. Similarly, the 
PHA-induced up-regulation of the IL-4R was also found to be sen-
sitive to IFN-y (Fig 4B). PHA stimulation induced IL-4R expres-
sion to a similar extent in atopic and normal PBMe. In both groups 
reduction of IL-4R expression was observed when the cells were 
co-treated with IFN-y. 
DISCUSSION 
This study demonstrates that IL-4R expression and IL-4 production 
are under the regulatory control of IFN-y. PBMC of AD patients 
exhibit higher IL-4 production and increased IL-4R mRNA ex-
pression than normal subjects. AD represents a disease that is 
characterized by enhanced IgE production [1-3]. Both IL, IL-4, 
and IFN-y have been shown to be intimately involved in the regula-
tion of IgE production. IL-4 acts as a switching factor for IgE [5 - 7] 
and IFN-y counteracts the IgE stimulatory effects of IL-4 [8-12] . 
It has been demonstrated that IFN-y inhibits IgE production by 
directly influencing B-cell functions [8], as well as by influencing 
T-cell functions [7]. Taken together, these observations suggest 
that AD represents a disease in which an imbalance between the 
production and functions ofIL-4 and IFN-y may be important. To 
further explore these interactions, we examined possible effects of 
IFN-y in vivo and in vitro on IL-4 production and IL-4R expres-
sion. 
IL-4 acts through interaction with its own rece£tor, the IL-4R. 
Resting lymphocytes constitutively express IL-4R l29]. We studied 
the expression of IL-4R on the mRNA level by Northern blot 
analysis. Freshly prepared unstimulated PBMC from patients with 
AD expressed higher amounts of IL-4R mRNA. It has been 
previously demonstrated that IL-4 acts as a potent upregulator of 
its own receptor [28,31,32]. Because IL-4 production in AD is 
enhanced compared to normal control subjects [22,23], it is pos-
sible that the increased IL-4 production accounts for this enhanced 
in vivo expression of IL-4R. This dysregulation ultimately may 
result in the hyper-production of IgE observed in these pa-
tients. 
Analysis of the proliferative response to IL-4 surprisingly re-
vealed a diminished proliferative response to this lymphokine in 
more than half the cases of AD. One possible explanation for this 
diminished proliferative response to IL-4 may be that, constituti-
vely, in vivo production of IL-4 leads to constant occupancy of the 
IL-4R and, in turn, when lymphocytes were re-exposed in vitro to 
IL-4, the cells could not respond with a normal proliferation pat-
tern. This possibility is supported by the observation that other 
IL-4 - dependent lymphocyte functions are also impaired in AD. In 
this regard, Vollenweider et al [33] reported that although in nor-
mal PEMC IL-4 stimulated IgE production, none or only a mar-
ginal enhancement ofIgE synthesis by IL-4 was reported in PBMC 
from AD patients. These data, together with our observations, may 
indicate that IL-4-dependent pathways are already stimulated in 
vivo and that further in vitro exposure to IL-4 exhibits only small 
effects. 
The data presented indicate that the production of IL-4 and 
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IL-4R are under the negative regulatory control of IFN-y. In vitro 
we found that IFN-y reduced enhanced IL-4R expression at the 
mRNA level. As the available data from humans and mice indicate 
that IL-4R mRNA production is strongly paralleled by IL-4R pro-
tein production and cell-surface expression [28,30,32]' it may be 
concluded that the down-regulation of IL-4R mRNA leads to a 
reduction in the surface expression of IL-4R as well. Whether the 
reduction at the mRNA level is due to increased degradation or 
reduced transcription of IL-4 mRNA requires further study. IL-4 
was measured in culture supernatants employing a bioassay that is 
based on the induction of CD23 expression by IL-4 on Ramos cells . 
This assay was originally described by Custer and Lotze [30] and 
combines a number of advantages. The induction of CD23 on this 
cell line is specifically induced only by IL-4, as other tested interleu-
kins, including IL-6 and GM-CSF (which also effect CD23 expres-
sion), failed to do so on Ramos cells. Moreover, a possible inhibitory 
effect ofIFN-y on CD23 was extended by the addition of an anti-
IFN-yR antibody to selected samples. As presentation of IL-4-
containing samples with anti - IL-4 prevented the induction of 
CD23 expression, this further underlines the specificity of this 
assay. 
We also report that treatment of AD patients for 12 weeks with 
rIFN-y resulted in an increase ofIL-4-dependent lymphocyte pro-
liferation in all but one individual. This reversal from pre-treatment 
findings may be related to a decrease in IL-4 production during the 
treatment period. Because the IL-4-IL-4R axis was found to be 
overstimulated in untreated patients, the extrapolation of our in 
vitro data may predict a similar inhibitory activity ofIFN-y on IL-4 
production and IL-4R expression in vivo. This would result in a 
normalized response to exogenously added IL-4 in the proliferation 
assay. 
One explanation for the overstimulation of the IL-4-IL-4R 
pathway in AD may be a dysfunction in IFN-y production that 
results in the lack of an important inhibitory factor for IL-4-IL-4R 
expression. In fact, we and others [21-23] demonstrated that AD 
patients show diminished IFN-y production upon in vitro stimula-
tion of PBMe. It has been reported that there is also a second 
negative feedback loop between IL-4 and IFN-y, i.e., IL-4 inhibits 
IFN-y production at least under certain culture conditions [34,35]' 
A second explanation for enhanced IL-4 production and dimin-
ished IFN-y secretion by PBMC from allergic patients may be that 
these diseases are characterized by an imbalance in IL-4 and IFN-y-
producing T cells in peripheral blood. Indeed, studies on T-cell 
clones from. allergic patients indicated an increased frequency of . 
IL-4-secretmg and a decreased number ofIFN-y-producing aller-
gen-specific T-cell clones [37,38]. Although this shift in the fre-
quency ofIL-4- a?-d ~FN-y-rroducing T-cell clones was reported 
by several groups, It still remams unclear whether freshly isolated T 
cells from allergic patients exhibit this biased pattern of cytokine 
production. 
Taken together, our observations suggest the following sequence 
of events. First, the cytokine profile in AD is characterized by endog-
IAI 
IB) 
PHA 
PHA + 
IFN·y 
I IL-4R mRNA I I GAPDH mRNA I 
Nl N2 N3 ADl AD2 AD3 A04 Nl N2 N3 ADl A02 AD3 A04 
Figure 4. Analysis ofIL-4R mRNA expression in three controls (N1-N3) 
and 4 AD patients (AD1-AD4). IL4R mRNA was analyzed on fresh PBMC 
(AJ and after 48-h stimulation with PHA (10,ug/ml) in the presence or 
absence of IFN-y (200U/ml) (B). Equal loading of the gels was demon-
strated by hybridization with the GAPDH housekeeping gene. 
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enous overproduction ofIL-4. Second, this hyperproduction ofIL-4 
leads to the increased expression of IL-4R. Third, this sequence is 
enhanced due to the reduced IFN-y production in AD, either as a 
result of lower frequencies ofIFN-y-producing T cells or second-
ary to the inhibitory activity oflL-4 on IFN-y production. In either 
case, these studies indicate that treatment of PEMC with IFN-y 
reduces IL-4 production and IL-4R expression in AD, thereby re-
storing responsiveness of AD PEMC to IL-4 . These data provide 
some explanation for the clinical efficacy of IFN -Y treatment in AD 
and provide a rationale for further investigations into the role of 
IFN-y in allergic diseases. 
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